9 studies found for:    9753033 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Prednisone;   Drug: Melphalan;   Drug: Thalidomide;   Drug: Defibrotide
2 Unknown  Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)
Condition: Multiple Mieloma
Intervention: Drug: PEG-Intron sc injection
3 Completed GEM05 for Patients With Multiple Myeloma Under 65 Years
Condition: Multiple Myeloma
Interventions: Drug: VBMCP/VBAD/Velcade;   Drug: Thalidomide/Dexamethasone;   Drug: Velcade/Thalidomide/Dexamethasone
4 Completed VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Velcade/Dexamethasone
5 Active, not recruiting Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up
6 Completed Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Melphalan;   Drug: Prednisone
7 Completed GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
Condition: Multiple Myeloma
Interventions: Drug: Melphalan/Prednisone/Velcade;   Drug: Thalidomide/Prednisone/Velcade
8 Completed Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Revlimid (CC-5013)
9 Recruiting Phase 1/2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: NPI-0052

Indicates status has not been verified in more than two years